CytomX Therapeutics, Inc. Earnings Recaps
Q3 2026
Nov 7, 2026
CytomX shares rose 2.3%, a roughly flat reaction. The company is advancing Varseta-M, but key evidence—including an overall survival update and a potential registrational strategy—remains pending.
Key takeaways
- CytomX plans to move Varseta-M monotherapy toward a potential registrational study in metastatic colorectal cancer in the first half of 2027.
- The company expects an integrated Phase 1 update in January, including the first look at overall survival; it is evaluating 8.6 mg/kg and 10 mg/kg doses every three weeks with adjusted ideal body weight dosing and upfront prophylaxis.
- The Varseta-M plus bevacizumab Phase 1 study continues to enroll late-line CRC patients, with initial clinical data anticipated in the first half of 2027. A separate Phase 1/2 combination study is planned to begin by year-end.
- CytomX has opened early cohorts in gastric and gastroesophageal junction cancer, and in EpCAM-selected pancreatic and biliary tract cancers, initially aiming to enroll about 20 patients per tumor type.
- The transcript excerpt ends during the CX-801 update, so it provides no further detail on that program.
Q1 2026
May 8, 2026
Shares dropped 3.6% following the earnings release, primarily due to cautious outlook and ongoing dose optimization challenges with Varseta-M. Investors responded negatively to the tentative guidance and need for further clinical dose refinement, tempering enthusiasm despite promising early data.
Key takeaways
- Market reaction of -3.6% reflects investor concerns about the pace of clinical development and lack of clear near-term approval catalyst.
- Varseta-M showed encouraging Phase I efficacy in late-line colorectal cancer with confirmed ORR between 20-32% and median PFS around 7 months.
- Dose optimization ongoing with 40 patients enrolled in latest cohorts; final dose selection delayed until potentially late 2026 or early 2027.
- Safety remains a key focus with updated management strategies aimed at reducing high-grade diarrhea, Varseta-M’s principal adverse event.
- Combination studies with bevacizumab initiated to support earlier-line use, but data for these will not be available until next year, contributing to cautious outlook.
Q3 2025
Nov 8, 2025
CytomX Therapeutics reported robust progress in its third quarter 2025 results, with encouraging interim Phase I data for its colorectal cancer drug candidate, CX-2051, demonstrating significant clinical activity and a well-tolerated safety profile.
Key takeaways
- CX-2051, targeting EpCAM in colorectal cancer, showed meaningful tumor reductions and a promising median progression-free survival of 5.8 months.
- The drug was generally well tolerated, with no significant safety issues, implying effective use of CytomX's proprietary masking technology.
- The company aims to expand the Phase I study to about 100 patients and initiate a Phase Ib study with bevacizumab in Q1 2026, enhancing treatment potential.
- A strategic addition to the team, Rachael Lester as Chief Business Officer, is expected to bolster corporate development efforts.
- CytomX remains committed to addressing unmet needs in oncology, with ambitions to establish CX-2051 as a new standard of care in late-stage colorectal cancer.